InvestorQ : How will the latest insulin injection approvals by the FDA, benefit Biocon?
Tisha Malhotra made post

How will the latest insulin injection approvals by the FDA, benefit Biocon?

Answer
user profile image
Mahima Roy answered.
3 months ago


The US FDA has given approval to Biocon Biologics for the insulin glargine injection, Semglee, meant to control high blood sugar in adults with diabetes. Semglee, has been co-developed by Biocon Biologics and Mylan. The Semglee a generic version of Sanofi’s Lantus insulin glargine. The medicine has annual sales of $1.68 billion. This approval had been stuck up over patent issues but the approval followed a favourable ruling from the US Patents office.